Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Open source

DOI
10.1186/s13058-015-0524-0
Published
2015-02-11
Container
Breast Cancer Res
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s13058-015-0524-0,
  title = {Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.},
  author = {Kren BT and  Unger GM and  Abedin MJ and  Vogel RI and  Henzler CM and  Ahmed K and  Trembley JH.},
  year = {2015},
  journal = {Breast Cancer Res},
  doi = {10.1186/s13058-015-0524-0},
  url = {https://doi.org/10.1186/s13058-015-0524-0}
}

RIS

TY  - JOUR
TI  - Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
AU  - Kren BT
AU  -  Unger GM
AU  -  Abedin MJ
AU  -  Vogel RI
AU  -  Henzler CM
AU  -  Ahmed K
AU  -  Trembley JH.
PY  - 2015
JO  - Breast Cancer Res
DO  - 10.1186/s13058-015-0524-0
UR  - https://doi.org/10.1186/s13058-015-0524-0
ER  - 

APA

BT, K., GM, U., MJ, A., RI, V., CM, H., K, A., & JH., T. (2015). Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.. Breast Cancer Res. https://doi.org/10.1186/s13058-015-0524-0

Source records